Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition
暂无分享,去创建一个
Omar Abdel-Wahab | Qiong Yang | Ayalew Tefferi | O. Abdel-Wahab | R. Levine | R. Schneider | A. Tefferi | Q. Wen | T. Lasho | A. Pardanani | J. Crispino | S. Malinge | Ross L Levine | John D Crispino | Benjamin H Goldenson | Sandeep Gurbuxani | Qiang Jeremy Wen | Benjamin Goldenson | Sébastien Malinge | Terra Lasho | Rebekka K Schneider | Lawrence J Breyfogle | Rachael Schultz | Laure Gilles | Priya Koppikar | Animesh Pardanani | Brady Stein | Ann Mullally | S. Gurbuxani | L. Gilles | Rachael F Schultz | B. Stein | Qiong Yang | A. Mullally | L. J. Breyfogle | Priya Koppikar | Sébastien Malinge | R. Levine
[1] Sandra A. Moore,et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.
[2] R. Mesa,et al. Current Outlook on Molecular Pathogenesis and Treatment of Myeloproliferative Neoplasms , 2012, Molecular Diagnosis & Therapy.
[3] H. Castro-Malaspina. Pathogenesis of myelofibrosis: role of ineffective megakaryopoiesis and megakaryocyte components. , 1984, Progress in clinical and biological research.
[4] I. Weissman,et al. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages , 2000, Nature.
[5] Jason Gotlib,et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. , 2012, The New England journal of medicine.
[6] K. Uozumi,et al. Establishment and characterization of a new human megakaryoblastic cell line (SET-2) that spontaneously matures to megakaryocytes and produces platelet-like particles , 2000, Leukemia.
[7] N. Mahmud,et al. Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. , 2007, Blood.
[8] M. Le Bousse-Kerdilès,et al. Involvement of the fibrogenic cytokines, TGF-beta and bFGF, in the pathogenesis of idiopathic myelofibrosis. , 2001, Pathologie-biologie.
[9] S. Verstovsek,et al. Investigational Janus kinase inhibitors , 2013, Expert opinion on investigational drugs.
[10] P. Guglielmelli,et al. Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis. , 2005, The American journal of pathology.
[11] A. Mead,et al. Practical management of patients with myelofibrosis receiving ruxolitinib , 2013, Expert review of hematology.
[12] A. Tefferi. JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. , 2012, Blood.
[13] Francisco Cervantes,et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. , 2012, The New England journal of medicine.
[14] A. Bergman,et al. Megakaryocytes regulate hematopoietic stem cell quiescence via Cxcl4 secretion , 2013, Nature Medicine.
[15] O. Abdel-Wahab,et al. Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis. , 2010, Blood.
[16] M. Weiss,et al. Early block to erythromegakaryocytic development conferred by loss of transcription factor GATA-1. , 2005, Blood.
[17] W. Vainchenker,et al. High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. , 1997, Blood.
[18] R. Hoffman,et al. A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis. , 2013, Blood.
[19] G. Superti-Furga,et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. , 2013, The New England journal of medicine.
[20] M. Cazzola,et al. Mutations and prognosis in primary myelofibrosis , 2013, Leukemia.
[21] F. Passamonti,et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Michael G. Kharas,et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. , 2010, Cancer cell.
[23] E. Hsiao,et al. Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche. , 2013, Cell stem cell.
[24] Xi C. He,et al. Megakaryocytes maintain homeostatic quiescence and promote post-injury regeneration of hematopoietic stem cells , 2014, Nature Medicine.
[25] M. Bryckaert,et al. Increased intraplatelet levels of platelet‐derived growth factor and transforming growth factor‐β in patients with myelofibrosis with myeloid metaplasia , 1991, British journal of haematology.
[26] B. Wiese,et al. Growth Factors , Cytokines , Cell Cycle Molecules Bone Morphogenetic Proteins Are Overexpressed in the Bone Marrow of Primary Myelofibrosis and Are Apparently Induced by Fibrogenic Cytokines , 2010 .
[27] M. Cazzola,et al. Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: Proceedings from the 6th international post‐ASH symposium , 2012, American journal of hematology.
[28] T. Kasahara,et al. Aurora kinase A critically contributes to the resistance to anti‐cancer drug cisplatin in JAK2 V617F mutant‐induced transformed cells , 2011, FEBS letters.
[29] T. Chou,et al. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.
[30] A. Migliaccio,et al. Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1(low) mice). , 2002, Blood.
[31] Q. Wen,et al. Aurora kinase A is required for hematopoiesis but is dispensable for murine megakaryocyte endomitosis and differentiation. , 2015, Blood.
[32] R. Kralovics,et al. Identification of oncostatin M as a JAK2 V617F‐dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[33] Sandra A. Moore,et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. , 2008, Cancer cell.
[34] W. Vainchenker,et al. Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. , 2002, Blood.
[35] Mark Coles,et al. Transgenic mice with hematopoietic and lymphoid specific expression of Cre , 2003, European journal of immunology.
[36] M Aguet,et al. Inducible gene targeting in mice , 1995, Science.
[37] R. Bayliss,et al. A Kinetic Test Characterizes Kinase Intramolecular and Intermolecular Autophosphorylation Mechanisms , 2013, Science Signaling.
[38] W. Vainchenker,et al. Prominent role of TGF-1 in thrombopoietin-induced myelofibrosis in mice , 2002 .
[39] J. D. Fitzpatrick,et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. , 2013, The New England journal of medicine.
[40] J. Crispino,et al. The Aurora Kinases in Cell Cycle and Leukemia , 2014, Oncogene.
[41] Mark A. Hall,et al. Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. , 2010, Blood.
[42] M. Tomasson,et al. The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. , 2008, Blood.
[43] T. Magnuson,et al. Aurora-A Kinase Is Essential for Bipolar Spindle Formation and Early Development , 2008, Molecular and Cellular Biology.
[44] S. Orkin,et al. A lineage‐selective knockout establishes the critical role of transcription factor GATA‐1 in megakaryocyte growth and platelet development , 1997, The EMBO journal.
[45] Anne E Carpenter,et al. Identification of Regulators of Polyploidization Presents Therapeutic Targets for Treatment of AMKL , 2012, Cell.